Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 28

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 28
---
 stock: 

        Net loss, basic and diluted 
        
       $
       (3,099
       )
        
       $
       (16,622
       )

        Weighted average number of shares of common stock outstanding, basic and diluted 

       54,096

       41,779

        Basic and diluted net loss per share of common stock 
        
       $
       (0.06
       )
        
       $
       (0.40
       )

       20

   K.Leases

   The Company has operating and finance leases for office space, laboratory facilities and various laboratory equipment, furniture and office equipment and leasehold improvements. The Company determines if an arrangement is a lease at contract inception. Lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company does not separate lease and non-lease components. Leases with a term of 12 months or less at commencement are not recorded on the unaudited condensed consolidated balance sheets. Lease expense for these arrangements is recognized on a straight-line basis over the lease term. The Company’s leases have remaining lease terms of less than 1 year and up to approximately 4 years, some of which include options to extend the leases for up to 5 years, and some which include options to terminate the leases within 1 year.
    
   The components of lease expense were as follows (in thousands): 

       Three months ended March 31,  
 Lease Cost   2025    2024  
 Finance lease cost:         
 Amortization of right-of-use assets  $1  $12 
 Total finance lease cost   1   12 
 Operating lease cost   118   93 
 Short-term lease cost   47   59 
 Variable lease cost   —   13 
 Less: sublease income   (39)  (39)
 Total lease costs  $127  $138 

   Supplemental cash flow information related to leases was as follows (in thousands):

       Three months ended March 31,  
   2025    2024  
 Cash paid for amounts included in the measurement of lease liabilities:         
 Operating cash flows from operating leases   215   123 
 Operating cash flows from short-term leases   47   59 
 Operating cash flows from variable lease